A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

412

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Plaque Psoriasis
Interventions
DRUG

Certolizumab pegol

Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection

Trial Locations (79)

Unknown

Ps0026 101, Brussels

Ps0026 103, Brussels

Ps0026 107, Brussels

Ps0026 102, Leuven

Ps0026 110, Maldegem

Ps0026 109, Mons

Ps0026 104, Namur

Ps0026 208, London

Ps0026 209, London

Ps0026 201, Markham

Ps0026 210, Newmarket

Ps0026 203, St. John's

Ps0026 212, Toronto

Ps0026 205, Waterloo

Ps0026 204, Winnipeg

Ps0026 301, Prague

Ps0026 303, Prague

Ps0026 302, Uherské Hradiště

Ps0026 408, Amiens

Ps0026 404, Lorient

Ps0026 409, Poitiers

Ps0026 403, Rennes

Ps0026 407, Toulon

Ps0026 512, Bielefeld

Ps0026 532, Bogen

Ps0026 525, Dresden

Ps0026 506, Düren

Ps0026 521, Freiburg im Breisgau

Ps0026 529, Gladbeck

Ps0026 523, Hamburg

Ps0026 518, Karlsruhe

Ps0026 519, Leipzig

Ps0026 537, Magdeburg

Ps0026 530, Memmingen

Ps0026 516, Merzig

Ps0026 517, München

Ps0026 527, München

Ps0026 515, Nuremberg

Ps0026 501, Potsdam

Ps0026 511, Quedlinburg

Ps0026 505, Remscheid

Ps0026 603, Athens

Ps0026 609, Athens

Ps0026 610, Athens

Ps0026 601, Chaïdári

Ps0026 606, Larissa

Ps0026 608, Pátrai

Ps0026 607, Piraeus

Ps0026 604, Thessaloniki

Ps0026 605, Thessaloniki

Ps0026 707, Bari

Ps0026 714, Bologna

Ps0026 711, Brescia

Ps0026 712, Catania

Ps0026 710, Florence

Ps0026 702, Genova

Ps0026 706, L’Aquila

Ps0026 701, Napoli

Ps0026 709, Roma

Ps0026 713, Roma

Ps0026 704, San Donato Milanese

Ps0026 715, Torino

Ps0026 708, Torrette DI Ancona

Ps0026 807, Badalona

Ps0026 809, Barcelona

Ps0026 812, Barcelona

Ps0026 804, Pontevedra

Ps0026 806, Sant Joan Despí

Ps0026 818, Vigo

Ps0026 902, Bradford

Ps0026 909, Dunfermline

Ps0026 914, Glasgow

Ps0026 916, Hertfordshire

Ps0026 911, Kingston upon Thames

Ps0026 905, Leeds

Ps0026 904, Newcastle upon Tyne

Ps0026 901, Salford

Ps0026 915, Wakefield

Ps0026 908, York

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04053881 - A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice | Biotech Hunter | Biotech Hunter